EXASOL AG

  • WKN: A0LR9G
  • ISIN: DE000A0LR9G9
  • Land: Deutschland

Nachricht vom 15.10.2021 | 08:00

EXASOL AG Announces Changes to its Leadership Structure (news with additional features)

DGAP-News: EXASOL AG / Key word(s): Strategic Company Decision
15.10.2021 / 08:00
The issuer is solely responsible for the content of this announcement.

Exasol Announces Changes to its Leadership Structure

  • Chief Commercial Officer Donald Kaye joins to lead Go-To-Market functions
  • Global functions and leadership streamlined to optimize effectiveness and agility

Nuremberg, Germany - 15 October 2021 - Exasol, the high-performance analytics database, today announced changes to the leadership structure of the organization. With the arrival of Donald Kaye, who joins as Chief Commercial Officer, the extended executive leadership team has been completed. In his role as CCO, Donald Kaye will assume the overall responsibility for managing and integrating all go-to-market functions, in particular sales, customer support, customer success management, and all marketing-related disciplines.

CEO Aaron Auld will continue to focus on actively shaping Exasol's corporate strategy and business model, as well as being responsible for Corporate Communications and the management of key business relationships. CTO Mathias Golombek will take over global Product Management in addition to leading the Research and Development (R&D) efforts. CFO & COO Jan-Dirk Henrich will continue to lead the Finance, IR, Legal, and HR functions and will additionally assume responsibility for internal IT operations.

The reorganization of responsibilities in the extended executive leadership team is accompanied by a streamlining of the go-to-market organization, which includes a relocation of global functions from the U.S. to Europe to ensure better integration with product development, R&D, and internal functions. This will also result in the departure of three members of the current leadership team. The commercial organization in the US, including local sales, customer service and field marketing, remains in place to support the continued growth in the U.S. market, a strategic region for Exasol.

Aaron Auld, CEO of Exasol, said, "As a company with high growth ambitions in a rapidly changing competitive environment, we need to regularly review our organizational structure and readjust where necessary. We are convinced that the relocation of core global functions to Europe, as well as the re-alignment of areas of responsibilities within the extended executive leadership team will strengthen our organization and improve agility and cross-functional collaboration."


About Exasol

Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol's analytics database - the fastest in the world - is trusted by the world's most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud or on-premises.

Exasol - accelerating insights from the world's data.

Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter

PR Contact:
Carla Gutierrez, Global Head of Communications at Exasol
Email: Carla.gutierrez@exasol.com

IR Contact:
Stefanie Winkler, Investor Relations Assistant at Exasol
Email: stefanie.winkler@exasol.com


Additional features:

File: Exasol Organization & Leadership Structure


15.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021